Phase I Studies

News Phase I Studies

• First acute intermittent porphyria patient treated with a gene therapy product

  Digna Biotech sets the first clinical trial in Spain to treat acute intermittent porphyria, a rare genetic disease that affects the biosynthesis of heme (a component of hemoglobin) and can cause significant neurological damage. This biotechnology company coordinates a phase I clinical trial in colla more

• arGEN-X initiates Phase Ib study of ARGX-110 in cancer

  arGEN-X announced the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery. ARGX-110 is a first-in-class CD70-targeting monoclonal antibody that addresses both known mechanisms of act more

• Kareus Therapeutics Announces Phase I trial for product in Alzheimer's Disease

  Kareus Therapeutics SA announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer’s dise more

Publications Phase I Studies

• Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors

  Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors Molecular Therapy advance online publication, April 23 2013. doi:10.1038/mt.2013.32 Authors: Neil Senzer, John Nemunaitis, Derek Nemunaitis, Cynthia Bedell, Gerald Edelman, Minal Barve, Robert Nunan, more

• Pharmacokinetic/pharmacodynamic studies of the 11β‐HSD1 inhibitor MK‐0916 in healthy subjects

  Summary Aims To characterize pharmacokinetic (PK) parameters of MK‐0916 and its safety and tolerability in lean, healthy males following single and multiple oral doses; to assess (by stable‐isotope labeling) in vivo inhibition of cortisone‐to‐cortisol conversion following oral MK‐0916. Me more

• Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

  Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study Leukemia advance online publication, February 19 2013. doi:10.1038/leu.2013.26 Authors: U Platzbecker, F Braulke, A Kündgen, K Götze, G B more

Market studies Phase I Studies

• Future Directions in Regenerative Medicine

  Big Pharma has begun investing in regenerative medicine: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a “tipping point”, after which no medical industry players will want to be left behind. This report covers the development of therapies to more

• C-Pharma, Inc. (CPBM) - Financial and Strategic SWOT Analysis Review

  C-Pharma, Inc. (C-Pharma), is a publicly held biotechnology company that is engaged in the development and commercialization of therapeutic and preventative products for the treatment of hepatitis C virus ("HCV"). The company about to complete its virus-like particles (VLP) technology, vaccine Pha more

• C-Pharma, Inc. (COBI) - Financial and Strategic SWOT Analysis Review

  C-Pharma, Inc. (C-Pharma), is a publicly held biotechnology company that is engaged in the development and commercialization of therapeutic and preventative products for the treatment of hepatitis C virus ("HCV"). The company about to complete its virus-like particles (VLP) technology, vaccine Phase more

Websites Phase I Studies